Amgen launches osteoporosis drug at $21,900 per treatment course

Amgen launched Evenity romosozumab-aqqg in the U.S. at $1,825 per month to treat osteoporosis in postmenopausal women at high risk of fracture.

Amgen Inc. (NASDAQ:AMGN) said the list price for a full course of Evenity is 34-74% lower than currently available anabolic agents over their full course of therapy. Evenity costs $21,900 for a 12-month treatment course based on the supporting clinical trials on its U.S. label. ...